Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms
Hamouda AK, Bautista MR, Akinola LS, Alkhlaif Y, Jackson A, Carper M, Toma WB, Garai S, Chen YC, Thakur GA, Fowler CD, Damaj MI. Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms. Neuropharmacology 2021, 190: 108568. PMID: 33878302, PMCID: PMC8169606, DOI: 10.1016/j.neuropharm.2021.108568.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsWithdrawal symptomsHypothermic effectMale miceAntinociceptive effectΑ4β2 nAChRsNicotine withdrawal-induced hyperalgesiaNAChR isoformsNicotine's antinociceptive effectsWithdrawal-induced hyperalgesiaNicotine withdrawal symptomsNicotine addiction treatmentAnxiety-like behaviorNicotinic acetylcholine receptorsDose-dependent mannerNociceptive responsesNicotine withdrawalNicotine intakeSomatic signsNicotine abstinencePharmacological effectsNicotine useAcetylcholine receptorsAffective symptomsPathophysiological processes